Drug Trial Radar · NCT01920711
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,822
Actual
Start
Jul 18, 2014
Primary completion
Jun 7, 2019
Study completion Jun 7, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 12, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696Drug
LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
ValsartanDrug
Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.Time frame: Total follow up time (up to 57 months)
Locations
715 sites in 43 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Muscle Shoals, Alabama
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Northridge, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Hartford, Connecticut
Novartis Investigative Site
New Haven, Connecticut
Novartis Investigative Site
Stamford, Connecticut
Novartis Investigative Site
West Haven, Connecticut
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Lake Worth, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Covington, Georgia
Novartis Investigative Site
Cumming, Georgia
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Evanston, Illinois
Novartis Investigative Site
Hazel Crest, Illinois
Novartis Investigative Site
Lombard, Illinois
Novartis Investigative Site
Maywood, Illinois
Novartis Investigative Site
Oakbrook Terrace, Illinois
Novartis Investigative Site
Peoria, Illinois
Novartis Investigative Site
Quincy, Illinois
Novartis Investigative Site
Louisville, Kentucky
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Hammond, Louisiana
Novartis Investigative Site
Lafayette, Louisiana
Novartis Investigative Site
Slidell, Louisiana
Novartis Investigative Site
Biddeford, Maine
Novartis Investigative Site
Portland, Maine
Showing 40 of 715 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.